(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 December 2015 - Actelion (SIX: ATLN) announced today that the New England Journal of Medicine (NEJM) has published the results of the oral, selective IP prostacyclin receptor agonist, selexipag, in patients with pulmonary arterial hypertension (PAH) [1]. Olivier Sitbon, MD, and primary author of the NEJM paper commented: 'Selexipag has the potential to improve PAH management, and the publication by the New England Journal of Medicine reflects the importance of our findings in the GRIPHON study. For the first time we see an effect on long-term outcome with an oral therapy that targets the prostacyclin pathway, a pathway that has for too long...
↧
